Back to Results
First PageMeta Content
Antidepressant / Selective serotonin reuptake inhibitor / Menopause / Medicine / Matter / IntelliPharmaCeutics / Pharmacology / Alcohols / Venlafaxine / Wyeth


DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857
Add to Reading List

Open Document

File Size: 45,71 KB

Share Result on Facebook

City

Philadelphia / Beltsville / /

Company

Robert Essner Wyeth Pharmaceuticals Inc. / Wyeth Pharmaceuticals Inc. / Robert Essner / Wyeth / /

Currency

ZAR / /

Event

FDA Phase / Product Issues / /

/

IndustryTerm

low energy / healthcare providers / treatment of major depressive disorder / /

MedicalCondition

concomitant illness / insomnia / depressive disorders / major depressive disorder / hypertension / seizures / eosinophilic pneumonia / mydriasis / seizure / serotonin syndrome / hyponatremia / Depression / interstitial lung disease / bipolar disorder / /

MedicalTreatment

antidepressant therapy / /

Organization

Food and Drug Administration / Division of Drug Marketing / Advertising / and Communications / Center for Drug Evaluation and Research / DEPARTMENT OF HEALTH / /

Person

Rand J. Econ / Xavier Vives / Thomas Abrams / Ramon Caminal / /

Position

investigator / Chairman and Chief Executive Officer / Director / /

Product

venlafaxine / EFFEXOR / Effexor XR / MACMIS / study / Effexor XR® (venlafaxine HCl) Tablets / /

ProvinceOrState

Pennsylvania / Maryland / /

URL

http /

SocialTag